|
UA68327C2
(en)
*
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
US7118754B1
(en)
*
|
1996-07-30 |
2006-10-10 |
Transgene S.A. |
Pharmaceutical composition for treating papillomavirus tumors and infection
|
|
AU4556597A
(en)
*
|
1996-09-24 |
1998-04-17 |
Bavarian Nordic Research Institute A/S |
Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
|
|
MY119381A
(en)
*
|
1996-12-24 |
2005-05-31 |
Gsf Forschungszentrum Umwelt |
Recombinant mva virus, and the use thereof
|
|
US6969609B1
(en)
*
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
FR2784997A1
(fr)
*
|
1998-10-22 |
2000-04-28 |
Transgene Sa |
Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
|
|
US20040265324A1
(en)
*
|
1999-03-23 |
2004-12-30 |
Cardosa Mary Jane |
Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
|
|
ATE412762T1
(de)
|
1999-05-28 |
2008-11-15 |
Helmholtz Zentrum Muenchen |
Vektor zur integration von heterologen sequenzen in poxvirusgenomen
|
|
US20150231227A1
(en)
*
|
2000-03-02 |
2015-08-20 |
Emory University |
Compositions and methods for generating an immune response
|
|
CN1291012C
(zh)
|
2000-03-14 |
2006-12-20 |
巴法里安诺迪克有限公司 |
修饰的安卡拉牛痘病毒(mva)的变株
|
|
RU2217162C2
(ru)
*
|
2000-04-10 |
2003-11-27 |
Государственный научный центр вирусологии и биотехнологии "Вектор" |
Вакцина против вирусных инфекций
|
|
DE10042598A1
(de)
*
|
2000-08-30 |
2002-03-28 |
Gsf Forschungszentrum Umwelt |
Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
|
|
AU2002211654A1
(en)
*
|
2000-10-10 |
2002-04-22 |
Genstar Therapeutics |
Minimal adenoviral vector and recombinant vaccines based thereon
|
|
US7445924B2
(en)
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
|
US7628980B2
(en)
|
2000-11-23 |
2009-12-08 |
Bavarian Nordic A/S |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
PL212047B1
(pl)
|
2000-11-23 |
2012-08-31 |
Bavarian Nordic As |
Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
|
|
US7740863B2
(en)
|
2001-04-06 |
2010-06-22 |
Merial |
Recombinant vaccine against West Nile Virus
|
|
DE10143490C2
(de)
*
|
2001-09-05 |
2003-12-11 |
Gsf Forschungszentrum Umwelt |
Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
|
|
DE10144664B4
(de)
*
|
2001-09-11 |
2005-06-09 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
|
|
EP2345665A3
(en)
|
2001-12-04 |
2012-02-15 |
Bavarian Nordic A/S |
Flavivirus NS1 subunit vaccine
|
|
JP5322252B2
(ja)
|
2001-12-20 |
2013-10-23 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
感染細胞からのポックスウイルスの採取および精製法
|
|
NZ536592A
(en)
|
2002-04-19 |
2007-01-26 |
Bavarian Nordic As |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
CN102703393A
(zh)
|
2002-05-16 |
2012-10-03 |
巴法里安诺迪克有限公司 |
表达插入痘病毒基因组中的同源基因的重组痘病毒
|
|
US7501127B2
(en)
|
2002-05-16 |
2009-03-10 |
Bavarian Nordic A/S |
Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
|
|
BR0310020A
(pt)
*
|
2002-05-16 |
2005-02-15 |
Bavarian Nordic As |
Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
|
|
JP2005537793A
(ja)
|
2002-09-05 |
2005-12-15 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
|
|
DE10249390A1
(de)
*
|
2002-10-23 |
2004-05-13 |
Ruprecht-Karls-Universität Heidelberg |
Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
|
|
WO2004048582A2
(en)
|
2002-11-25 |
2004-06-10 |
Bavarian Nordic A/S |
Recombinant poxvirus comprising at least two cowpox ati promoters
|
|
DE602004015418D1
(de)
*
|
2003-02-18 |
2008-09-11 |
Helmholtz Zentrum Muenchen |
Rekombinantes mva und verfahren zur erzeugung davon
|
|
EP1601333B1
(en)
*
|
2003-02-20 |
2013-01-23 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services |
Novel insertion sites in pox vectors
|
|
DE602004018284D1
(de)
|
2003-03-27 |
2009-01-22 |
Ottawa Health Research Inst |
Mutante vesicular stomatitis viren und deren verwendungen
|
|
US7731974B2
(en)
*
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
US7163685B2
(en)
*
|
2003-04-16 |
2007-01-16 |
City Of Hope |
Human cytomegalovirus antigens expressed in MVA and methods of use
|
|
GB2402391A
(en)
*
|
2003-06-04 |
2004-12-08 |
Oxxon Pharmaccines Ltd |
Fowlpox recombinant genome
|
|
DK1648931T3
(da)
|
2003-07-21 |
2011-03-07 |
Transgene Sa |
Multifunktionelle cytokiner
|
|
US20100189747A1
(en)
*
|
2003-07-31 |
2010-07-29 |
Raymond Weinstein |
Compositions and methods for treating or preventing hiv infection
|
|
EP1518932A1
(en)
*
|
2003-09-29 |
2005-03-30 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Modified vaccinia virus Ankara (MVA) mutant and use thereof
|
|
EP1845164B1
(en)
*
|
2003-11-24 |
2010-06-16 |
Bavarian Nordic A/S |
Promoters for expression in modified vaccinia virus ankara
|
|
US7638132B2
(en)
|
2003-12-05 |
2009-12-29 |
National University Corporation Hokkaido University |
Highly safe smallpox vaccine virus and vaccinia virus vector
|
|
EP1683870A1
(en)
*
|
2005-01-24 |
2006-07-26 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vaccines based on the use of MVA
|
|
US20090269365A1
(en)
*
|
2005-04-20 |
2009-10-29 |
University Of Washington |
Immunogenic vaccinia peptides and methods of using same
|
|
CA2670804A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Sanofi Pasteur Inc. |
Immunological composition
|
|
HUE030533T2
(hu)
*
|
2006-06-20 |
2017-05-29 |
Transgene Sa |
Eljárás poxvírusok és poxvírus-készítmények elõállítására
|
|
WO2008076157A2
(en)
*
|
2006-09-08 |
2008-06-26 |
Duke University |
Modified vaccinia ankara virus vaccine
|
|
CA2663034C
(en)
|
2006-09-15 |
2016-05-03 |
Ottawa Health Research Institute |
Oncolytic rhabdovirus
|
|
DK2073837T3
(da)
|
2006-10-06 |
2014-09-29 |
Bavarian Nordic Inc |
Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer
|
|
US20080241139A1
(en)
*
|
2006-10-31 |
2008-10-02 |
Regents Of The University Of Colorado |
Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
|
|
CA2676129A1
(en)
*
|
2007-01-26 |
2008-08-07 |
The Regents Of The University Of Colorado |
Methods of modulating immune function
|
|
EP2208737B1
(en)
|
2007-05-03 |
2017-07-05 |
Lysomab GmbH |
Complement factor H-derived short consensus repeat-antibody constructs
|
|
US8003363B2
(en)
*
|
2007-05-14 |
2011-08-23 |
Bavarian Nordic A/S |
Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
|
|
JP2010526546A
(ja)
*
|
2007-05-14 |
2010-08-05 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製
|
|
US8003364B2
(en)
*
|
2007-05-14 |
2011-08-23 |
Bavarian Nordic A/S |
Purification of vaccinia viruses using hydrophobic interaction chromatography
|
|
US20100285050A1
(en)
*
|
2007-10-05 |
2010-11-11 |
Isis Innovation Limited |
Compositions and Methods
|
|
BRPI0800485B8
(pt)
*
|
2008-01-17 |
2021-05-25 |
Univ Minas Gerais |
vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
|
|
CN102257134B
(zh)
|
2008-02-12 |
2014-03-05 |
赛诺菲巴斯德有限公司 |
使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
|
|
WO2009152969A1
(en)
*
|
2008-06-20 |
2009-12-23 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus measles vaccine
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
WO2010127115A1
(en)
|
2009-04-30 |
2010-11-04 |
Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) |
Modified immunization vectors
|
|
TWI555531B
(zh)
|
2009-08-07 |
2016-11-01 |
傳斯堅公司 |
用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物
|
|
US9005632B2
(en)
|
2009-11-20 |
2015-04-14 |
Takeda Vaccines, Inc. |
Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
|
|
JP5798124B2
(ja)
*
|
2009-11-20 |
2015-10-21 |
タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. |
ワクチン構築物におけるポックスウイルスエレメントに関する免疫原性組成物
|
|
EP2550362B1
(en)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv glycoproteins and recombinant vectors
|
|
GB201006405D0
(en)
|
2010-04-16 |
2010-06-02 |
Isis Innovation |
Poxvirus expression system
|
|
US20110262965A1
(en)
*
|
2010-04-23 |
2011-10-27 |
Life Technologies Corporation |
Cell culture medium comprising small peptides
|
|
US20140093556A1
(en)
|
2011-01-28 |
2014-04-03 |
Sanofi Pasteur Sa |
Immunological Compositions Against HIV
|
|
WO2012151272A2
(en)
|
2011-05-02 |
2012-11-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
CA2832109C
(en)
|
2011-06-10 |
2021-07-06 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
|
EP2739293B1
(en)
*
|
2011-08-05 |
2020-06-10 |
SillaJen Biotherapeutics, Inc. |
Methods and compositions for production of vaccina virus
|
|
EP2568289A3
(en)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
|
CN104039968B
(zh)
*
|
2011-09-26 |
2018-10-26 |
赛拉福柯蒂斯公司 |
非b亚型gag蛋白在慢病毒包装中的应用
|
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
|
DK2788021T3
(en)
|
2011-12-09 |
2017-04-10 |
Bavarian Nordic As |
POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
|
|
EP2620446A1
(en)
|
2012-01-27 |
2013-07-31 |
Laboratorios Del Dr. Esteve, S.A. |
Immunogens for HIV vaccination
|
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
|
CN104640564B
(zh)
|
2012-07-10 |
2020-08-04 |
特兰斯吉恩股份有限公司 |
分枝杆菌抗原疫苗
|
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
|
WO2014043535A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions for the treatment of cancer
|
|
JP6430949B2
(ja)
|
2012-10-23 |
2018-11-28 |
エモリー ユニバーシティ |
Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
|
|
US20140286981A1
(en)
|
2013-03-14 |
2014-09-25 |
Wisconsin Alumni Research Foundation |
Broadly reactive mosaic peptide for influenza vaccine
|
|
DE102013004595A1
(de)
|
2013-03-15 |
2014-09-18 |
Emergent Product Development Germany Gmbh |
RSV-Impfstoffe
|
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
EP3092000A1
(en)
|
2014-01-09 |
2016-11-16 |
Transgene SA |
Fusion of heterooligomeric mycobacterial antigens
|
|
GB201412494D0
(en)
|
2014-07-14 |
2014-08-27 |
Ospedale San Raffaele And Fond Telethon |
Vector production
|
|
ES2865150T3
(es)
|
2014-09-26 |
2021-10-15 |
Beth Israel Deaconess Medical Ct Inc |
Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
|
|
US11701418B2
(en)
|
2015-01-12 |
2023-07-18 |
Geovax, Inc. |
Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
|
|
ES3011733T3
(en)
|
2015-02-13 |
2025-04-08 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
PT3390430T
(pt)
|
2015-12-15 |
2019-11-20 |
Janssen Vaccines & Prevention Bv |
Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
|
|
EP3402802B1
(en)
*
|
2016-01-08 |
2023-04-12 |
Geovax, Inc. |
Compositions and methods for generating an immune response to a tumor associated antigen
|
|
BR112018015696A2
(pt)
|
2016-02-03 |
2018-12-26 |
Geovax Inc |
composições e métodos para gerar uma resposta imune para um flavivírus
|
|
CN109152827B
(zh)
*
|
2016-02-25 |
2023-07-21 |
纪念斯隆凯特琳癌症中心 |
重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
|
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
|
JP6595132B2
(ja)
|
2016-06-16 |
2019-10-23 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Ｈｉｖワクチン製剤
|
|
CA3035759A1
(en)
|
2016-09-02 |
2018-03-08 |
Janssen Vaccines & Prevention B.V. |
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
|
|
AR109528A1
(es)
|
2016-09-15 |
2018-12-19 |
Janssen Vaccines & Prevention Bv |
Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih
|
|
US20190328869A1
(en)
|
2016-10-10 |
2019-10-31 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
CN110958887B
(zh)
|
2017-06-15 |
2023-10-31 |
扬森疫苗与预防公司 |
编码hiv抗原的痘病毒载体及其使用方法
|
|
KR20240113607A
(ko)
|
2017-06-21 |
2024-07-22 |
트랜스진 |
개인 맞춤형 백신
|
|
AU2018304502B2
(en)
|
2017-07-19 |
2022-03-31 |
Janssen Vaccines & Prevention B.V. |
Trimer stabilizing HIV envelope protein mutations
|
|
US20190022212A1
(en)
|
2017-07-21 |
2019-01-24 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
|
|
US20190083620A1
(en)
|
2017-09-18 |
2019-03-21 |
Janssen Vaccines & Prevention B.V. |
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
|
|
US11311612B2
(en)
|
2017-09-19 |
2022-04-26 |
Geovax, Inc. |
Compositions and methods for generating an immune response to treat or prevent malaria
|
|
EP3973973A1
(en)
|
2017-10-31 |
2022-03-30 |
KaliVir Immunotherapeutics, Inc. |
Platform oncolytic vector for systemic delivery
|
|
CN111315407B
(zh)
|
2018-09-11 |
2023-05-02 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
|
TW202110476A
(zh)
|
2019-05-22 |
2021-03-16 |
荷蘭商傑森疫苗防護公司 |
於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
|
|
AU2020366460A1
(en)
*
|
2019-10-16 |
2022-03-24 |
Kalivir Immunotherapeutics, Inc. |
Producer viruses for generation of retroviruses in SITU
|
|
CA3161633A1
(en)
|
2019-11-14 |
2021-05-20 |
Aelix Therapeutics, S.L. |
Dosage regimens for vaccines
|
|
EP3842065A1
(en)
|
2019-12-23 |
2021-06-30 |
Transgene |
Process for designing a recombinant poxvirus for a therapeutic vaccine
|
|
WO2021260065A1
(en)
|
2020-06-24 |
2021-12-30 |
Consejo Superior De Investigaciones Científicas (Csic) |
Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
|
|
EP3928789A1
(en)
|
2020-06-24 |
2021-12-29 |
Consejo Superior de Investigaciones Científicas (CSIC) |
Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
|
|
CA3197371A1
(en)
|
2020-11-19 |
2022-05-27 |
Kalivir Immunotherapeutics, Inc. |
Oncolytic immunotherapy by tumor micro-environment remodeling
|
|
EP4329786A4
(en)
|
2021-04-30 |
2024-12-11 |
KaliVir Immunotherapeutics, Inc. |
Oncolytic viruses for modified mhc expression
|
|
WO2022269003A1
(en)
|
2021-06-23 |
2022-12-29 |
Consejo Superior De Investigaciones Cientificas |
MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
|
|
EP4108257A1
(en)
|
2021-06-23 |
2022-12-28 |
Consejo Superior De Investigaciones Científicas |
Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
|
|
WO2023077147A2
(en)
|
2021-11-01 |
2023-05-04 |
Pellis Therapeutics, Inc. |
T-cell vaccines for patients with reduced humoral immunity
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
US20230364227A1
(en)
|
2022-05-12 |
2023-11-16 |
Pellis Therapeutics, Inc. |
Poxvirus adjuvant for t-cell vaccination
|
|
EP4316514A1
(en)
|
2022-08-03 |
2024-02-07 |
Consejo Superior de Investigaciones Científicas (CSIC) |
Mva-based vectors and their use as vaccine against sars-cov-2
|
|
EP4680277A1
(en)
|
2023-03-17 |
2026-01-21 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Hbv antigen formulation for treating hepatitis b
|
|
WO2025172435A1
(en)
|
2024-02-13 |
2025-08-21 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Hbv antigen formulation for treating hepatitis b
|
|
WO2026041811A1
(en)
|
2024-08-23 |
2026-02-26 |
Transgene |
Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell
|